Previous studies demonstrated that the engineered fusion protein anti-CD19(Fab)-LDM, which comprises the chemo-drug lidamycin and anti-CD19(Fab) antibody, showed targeted cytotoxicity against lymphoma cells both in vitro and in vivo (23). The gene discussed is CD19; the disease is lymphoma.